SCHEMBL13250522

SCHEMBL13250522

Cc1ccc(C(c2cccc(CN3CCCNCc4cccc(c4)CNCCC3)c2)c2cccc(CN3CCCNCc4cccc(c4)CNCCC3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 6/20 0.46
▸ CYP3A4 P08684 2/20 0.39
▸ CNR1 P21554 2/20 0.39
▸ CHRM2 P08172 2/20 0.39
▸ CHRM1 P11229 2/20 0.39
▸ ADRA2C P18825 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HPN P05981 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ DRD1 P21728 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250544 0.92 CXCR4 (0.55) CXCR4CHRM2CHRM1ADRA2CSMN1; SMN2
SCHEMBL13447599 0.91 CXCR4 (0.52) CXCR4CYP3A4CNR1CHRM2CHRM1
SCHEMBL13250519 0.91 CXCR4 (0.43) CXCR4CHRM2CHRM1ADRA2CCYP2D6
SCHEMBL13250527 0.89 ALDH1A1 (0.47) CXCR4CNR1CHRM2CHRM1ADRA2C
SCHEMBL13250526 0.89 SMN1; SMN2 (0.44) CXCR4CHRM2CHRM1ADRA2CSMN1; SMN2
SCHEMBL13250532 0.87 CXCR4 (0.51) CXCR4CYP3A4CNR1CHRM2CHRM1
SCHEMBL13250487 0.86 CXCR4 (0.64) CXCR4CYP3A4CNR1CHRM2CHRM1
SCHEMBL13250528 0.85 CXCR4 (0.47) CXCR4CNR1CHRM2CHRM1ADRA2C
SCHEMBL13250543 0.85 CXCR4 (0.50) CXCR4CHRM2CHRM1ADRA2CCYP2D6
SCHEMBL13250547 0.83 CXCR4 (0.50) CXCR4CHRM2CHRM1ADRA2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS CXCR4 555/4885CYP3A4 1015/4885CNR1 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback